Global Human Growth Hormones Market to reach USD 10 billion by 2030, driven by increasing prevalence of growth hormone deficiency, product approvals, and adoption of recombinant HGH. North America dominates the market, with key players including Novo Nordisk, Pfizer, and Eli Lilly. Market growth is fueled by advancements in biotechnology and rising demand for targeted therapies, despite challenges like stringent regulations and high treatment costs.